Hypersensitivity
Conditions
Keywords
Grass pollen allergy, subcutaneous immunotherapy, allergy vaccine, dose regimen
Brief summary
BM32 is a product for immunotherapy of grass pollen allergies. It consists of 4 different recombinant proteins (BM321, BM322, BM325 and BM326) adsorbed on alhydrogel. This prospective, double-blind. placebo controlled, mono-centric trial investigates the levels of allergen specific IgG antibodies following 3, 4 or 5 subcutaneous injections before the grass pollen season.
Detailed description
The aim of this study is to further optimize the immunization schedule by * moving the last injection into beginning of the grass pollen season for all study arms in order to ensure highest possible IgG4 levels when they are needed - i.e. at the peak of the grass pollen season, * administration of more than 3 pre-seasonal injections in order to build up sufficiently high levels of IgG4 already in the first year of treatment , and * dosing during the beginning of the grass pollen season to establish safety in this setting The effect of such optimized immunization schedule on the induction of an IgG4 immune response as a surrogate parameter for efficacy will be studied. The Total Nasal Symptom Score (TNSS) before and after the treatment and Combined Symptom-Medication Score (SMS) during the grass pollen season will be evaluated as secondary endpoints. This will allow intra-individual comparison of seasonal symptom data and responsiveness in the chamber setting.
Interventions
BIOLOGICALBM32
BM32 is a mixture of 4 different recombinant proteins directed at the major grass pollen allergens, adsorbed on aluminum hydroxide
BIOLOGICALPlacebo
Placebo contains aluminum hydroxide only
Sponsors
Biomay AG
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* The subjects are grass pollen allergic but otherwise healthy. Healthy subjects are defined as individuals who are free from clinically significant illness or disease as determined by their medical history (including family), physical examination, laboratory studies, and other tests. * They are aged 18 to 60 years inclusive. * They have a history of seasonal allergic rhinitis (SAR) to grass pollen. * They have a normal electrocardiogram without clinically significant abnormalities. * They exhibit a moderate to severe response to approximately 1500 grass pollen grains/m3 after the first 2h in the Vienna Challenge Chamber, which is defined as a nasal symptom score (TNSS) of at least 6. (Nasal symptom score is the sum of nasal obstruction, rhinorrhoea, itchy nose and sneezing, each of which have been scored on a scale from 0 to 3). * They have a positive skin prick test with a wheal diameter \>5mm for grass pollen extract at the screening visit. * They have a positive serum IgE test for timothy grass pollen and to rPhl p 1+rPhl p 5 at the screening visit (ImmunoCAP ≥3.5 kUA/l; i.e ≥ class 2).. * There are no conditions or factors which would make the subject unlikely to be able to stay in the chamber for 6 hours. * They are capable of giving informed consent which includes compliance with the requirements and restrictions listed in the consent form. * They are available to complete all study measurements
Exclusion criteria
* Sensitization to Phl p 7 * Pregnant, lactating or sexually active women with childbearing potential who are not using a medically accepted birth control method (pregnancy to be controlled by a pregnancy dipstick test). * On examination the subject is found to have any structural nasal abnormalities or nasal polyposis, a history of frequent nosebleeds, recent nasal surgery or ongoing upper respiratory tract infection which in the Responsible Physician's opinion renders the subject unsuitable for participation in the study. * Any respiratory disease other than mild stable asthma that is controlled with occasional use of as-needed short-acting beta-agonists and associated with normal lung function. * The subject is concurrently participating or has participated in any clinical study in the previous month. * Participation in a SIT trial for grass pollen allergy in the three years prior to this study. * Past or present disease, which as judged by the investigator, may affect the outcome of this study. These diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, haematological disease, neurological disease, endocrine disease or pulmonary disease (including but not confined to chronic bronchitis, emphysema, bronchiectasis or pulmonary fibrosis).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Titer of allergen specific IgG4 antibodies | approximately 6 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Total nasal symptom score upon pollen challenge (TNSS) | Change from baseline at 9 months | Sensitivity to a grass pollen challenge in an environmental exposure chamber |
| Mean daily combined symptom and medication score (SMS) | 2 weeks | — |
| Well-being via visual analog scale | 2 weeks | — |
| Titers of allergen specific IgG antibodies | Up to 9 months | — |
Other
| Measure | Time frame | Description |
|---|---|---|
| Incidence of treatment emerging adverse events | up to 9 months | Frequency and severity of IMP related adverse events |
Countries
Austria
Outcome results
None listed